Food allergies can be overcome in several ways: some people naturally outgrow them, others undergo treatments that raise their tolerance threshold, and newer therapies aim to turn off the allergic response entirely. The right path depends on which food you’re allergic to, your age, and how severe your reactions are. Here’s what actually works, what’s available now, and what the different options look like in practice.
Many Food Allergies Are Outgrown
The most common childhood food allergies, including milk, egg, wheat, and soy, are also the ones most likely to resolve on their own. About 80% of children with these allergies outgrow them, typically by age 16. The process is gradual: the immune system slowly stops recognizing the protein as a threat, and tolerance builds over years without any medical intervention.
Peanut and tree nut allergies are a different story. Only about 20% to 25% of children with a peanut allergy outgrow it, and most who do will have done so by age 8. Shellfish and fish allergies also tend to persist into adulthood. If you’re an adult with a food allergy that started in childhood, it’s less likely to resolve on its own, but it’s not impossible. Periodic testing through a supervised oral food challenge (where you eat the food in small, increasing amounts under medical observation) is the only reliable way to confirm whether an allergy has truly resolved. Skin tests and blood work alone can stay positive even after you’ve become tolerant.
Oral Immunotherapy: The Most Established Treatment
Oral immunotherapy, or OIT, is the most studied approach for actively treating food allergies. It works by feeding you tiny, precisely measured amounts of the allergen daily, then gradually increasing the dose over months until your immune system learns to tolerate it. Across clinical trials, OIT desensitizes roughly 60% to 80% of patients to peanut, egg, and milk.
An important distinction here: desensitization is not the same as being “cured.” Desensitization means your reaction threshold goes up while you continue eating the allergen regularly. If you stop your daily maintenance dose for an extended period, the protection can fade. The more ambitious goal, sometimes called sustained unresponsiveness or remission, means you can stop therapy for weeks to months and still tolerate the food. True tolerance, where you can eat the food freely with no treatment and no risk of the allergy returning, is the ultimate target, but current FDA-approved therapies reliably deliver desensitization rather than full tolerance.
For peanut allergy specifically, there is an FDA-approved OIT product with a daily maintenance dose of 300 mg of peanut protein (roughly one peanut). The treatment requires months of gradual dose increases under medical supervision before reaching maintenance. During treatment, you’ll need to follow dietary and exercise restrictions around dosing times, since physical activity can increase the risk of a reaction. Side effects are mostly mild, like stomach discomfort and itching, but moderate to severe reactions do occur.
Sublingual Immunotherapy: A Gentler Alternative
Sublingual immunotherapy, or SLIT, takes a similar concept but uses much smaller doses held under the tongue rather than swallowed. The allergen absorbs through the tissue in your mouth, and the doses involved are roughly a thousand times smaller than those used in OIT. For peanut SLIT, the daily maintenance dose is around 3.7 mg compared to OIT’s 2,000 mg or more.
The tradeoff is predictable: SLIT is safer but initially less potent. In a head-to-head comparison, 12 months of peanut SLIT increased the amount of peanut a person could tolerate by about 22 times their baseline, while OIT delivered a 141-fold increase. That said, recent studies using higher SLIT doses have closed that gap considerably, approaching OIT-level results. About 95% of SLIT doses are symptom-free once you exclude minor mouth itching, and stomach side effects are rare. There’s no need for exercise restrictions around dosing.
SLIT is particularly appealing if you’ve had bothersome side effects during OIT or simply prefer a lower-risk option. Long-term SLIT has also been shown to induce sustained unresponsiveness, meaning the protection can persist even after stopping treatment.
Skin Patch Therapy for Young Children
Epicutaneous immunotherapy delivers tiny amounts of allergen through a patch worn on the skin. A Phase 3 trial published in the New England Journal of Medicine tested a patch containing 250 micrograms of peanut protein (about one-thousandth of a peanut) in children aged 1 to 3. After 12 months of daily wear, 67% of children in the treatment group were desensitized, compared to 33.5% on placebo. Side effects were primarily mild-to-moderate skin reactions at the patch site, which decreased over time. This approach is not yet widely available but is moving through the regulatory process.
The patch is especially significant because it targets toddlers, an age group where OIT can be difficult to administer and where early intervention may offer the best window for changing the immune response.
A Medication That Raises Your Safety Threshold
In February 2024, the FDA approved an injectable medication for food allergy that works differently from immunotherapy. Rather than training your immune system to accept specific foods, it blocks the antibody (IgE) responsible for triggering allergic reactions. It’s approved for adults and children 1 year and older who are allergic to one or more foods, and it reduces the severity of reactions from accidental exposure.
The approval was based on a study of 168 people allergic to peanut plus at least two other foods like milk, egg, wheat, cashew, hazelnut, or walnut. This is the first medication approved to protect against multiple food allergies simultaneously. It doesn’t eliminate the allergy or allow you to eat the food freely. Instead, it acts as a safety net, making accidental exposures less dangerous. Some allergists also use it alongside OIT to reduce side effects during dose escalation.
Preventing Food Allergies in Infants
If you’re reading this as a parent of a young baby, prevention may be the most powerful tool available. Current guidelines from the FDA and the Dietary Guidelines for Americans recommend introducing peanut-containing foods as early as 4 to 6 months for infants at high risk, meaning babies with severe eczema, an existing egg allergy, or both. This early introduction significantly reduces the risk of developing a peanut allergy in the first place.
This recommendation reversed decades of advice that told parents to delay allergen introduction. The shift came after landmark research showed that early, regular exposure to peanut protein trained the infant immune system toward tolerance rather than allergy. For babies without these risk factors, introducing common allergens alongside other solid foods around 6 months is still considered beneficial. Age-appropriate forms matter: thin peanut butter mixed into purees works for infants, while whole peanuts are a choking hazard.
The Role of Gut Health
Children with food allergies consistently show lower diversity in their gut bacteria, with reduced levels of several beneficial bacterial groups. This isn’t just a correlation. The gut microbiome plays a direct role in training the immune system to tolerate food proteins rather than attack them. Dietary strategies using prebiotics (fiber that feeds beneficial bacteria), probiotics (live beneficial bacteria), and combinations of both have shown potential for restoring microbial balance and promoting immune tolerance. Results vary depending on the specific bacterial strains used, the timing of the intervention, and the individual, so there’s no single probiotic supplement proven to reverse a food allergy. But early-life microbiome support is an active area of clinical development, and maintaining a diverse, fiber-rich diet is a reasonable foundation regardless.
Choosing a Path Forward
Your options depend heavily on your specific situation. If your child has a milk, egg, wheat, or soy allergy, there’s a strong chance they’ll outgrow it, and periodic oral food challenges can track that progress. For peanut and tree nut allergies, active treatment through OIT or SLIT offers the best chance of increasing tolerance. If you’re managing allergies to multiple foods, the newly approved IgE-blocking medication provides broader protection against accidental exposure. And for the youngest children, a skin patch may soon offer a low-burden treatment option.
None of these approaches is a guaranteed cure. The realistic goal for most people right now is desensitization: raising the amount of a food you can safely tolerate so that an accidental bite of something at a restaurant doesn’t become a medical emergency. For many families, that shift alone is life-changing.